"GLI1 Subcellular Localization and Overexpression As Prognostic Factors for Disease-Free Survival in Colorectal Carcinoma"

Overview

Journal J Gastrointest Cancer

Publisher Springer

Specialties Gastroenterology
Oncology

Date 2024 Jul 17

PMID 39018008

Authors

Tahseen Bilal Rather

Ishrat Parveiz

Gowhar Rashid

Kulsum Akhtar

Syed Mudassar

Rauf A Wani

Syed Besina

Rather Izhar Ul Haq

Affiliations

Soon will be listed here.

Abstract

Purpose: Glioma-associated oncogene homolog-1 (GLI1) is amplified in human glioblastoma, and there is growing evidence suggesting its significant role in tumor development and metastasis. Our aim was to investigate the role of the GLI-1 gene in the progression of colorectal cancer (CRC) and its correlation with various clinicopathological features. Additionally, we examined the impact of the GLI-1 gene and other factors on the prognosis of CRC.

Methods: We analyzed a total of 98 confirmed CRC cases and adjacent normal tissue controls. Patients suspected of having colon cancer underwent a colonoscopy and targeted biopsy, while those with rectal cancer underwent CT scans and MRI. GLI1 expression was detected using real-time PCR assay, Western blotting, and immunohistochemistry.

Results: The GLI1 gene was observed to be overexpressed in tumor tissues at both the protein and mRNA levels (p < 0.05). In addition, GLI1 overexpression was significantly associated with various factors such as tumor invasion (T3/T4), presence of lymph nodes, lymph node metastasis (LNM), stage (III/IV), tumor site (colon), tumor size (≥ 3 cm), localization (nucleocytoplasmic), strong staining intensity and recurrence (p < 0.05). The results of survival analysis showed that the patients with overexpression of GLI1 had a significantly lower DFS rate which was 21 months compared to those with normal expression who had 31 months (p < 0.05). Moreover, individuals with early onset disease (15 months) were more likely to have cytoplasmic localization of the GLI1 gene as opposed to nucleo-cytoplasmic localization of GLI1 which presented late-onset disease( 23 months) (p < 0.05). Finally, Stage and PNI (p < 0.05) were found to independently affect outcomes of CRC according to Cox regression analysis.

Conclusion: High expression of GLI-1 in CRC is associated with adverse pathology and poor prognosis for patients. The correlation between cytoplasmic localization of GLI-1 and reduced disease-free survival holds potential for guiding prognosis and treatment. Further research is needed to develop strategies targeting GLI-1 for improved outcomes.

References

Paschke S, Jafarov S, Staib L, Kreuser E, Maulbecker-Armstrong C, Roitman M . Are Colon and Rectal Cancer Two Different Tumor Entities? A Proposal to Abandon the Term Colorectal Cancer. Int J Mol Sci. 2018; 19(9). PMC: 6165083. DOI: 10.3390/ijms19092577. View

Wahab S, Alshahrani M, Ahmad M, Abbas H . Current trends and future perspectives of nanomedicine for the management of colon cancer. Eur J Pharmacol. 2021; 910:174464. DOI: 10.1016/j.ejphar.2021.174464. View

Papamichael D, Audisio R, Glimelius B, de Gramont A, Glynne-Jones R, Haller D . Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. Ann Oncol. 2014; 26(3):463-76. DOI: 10.1093/annonc/mdu253. View

Heemskerk-Gerritsen B, Rookus M, Aalfs C, Ausems M, Collee J, Jansen L . Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2014; 136(3):668-77. DOI: 10.1002/ijc.29032. View

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-42. DOI: 10.1056/NEJMoa032691. View

Keum N, Giovannucci E . Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019; 16(12):713-732. DOI: 10.1038/s41575-019-0189-8. View

Toma M, Belusica L, Stavarachi M, Apostol P, Spandole S, Radu I . Rating the environmental and genetic risk factors for colorectal cancer. J Med Life. 2019; 5(Spec Issue):152-159. PMC: 6880217. View

Haggar F, Boushey R . Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2010; 22(4):191-7. PMC: 2796096. DOI: 10.1055/s-0029-1242458. View

Huang D, Wang Y, Tang J, Luo S . Molecular mechanisms of suppressor of fused in regulating the hedgehog signalling pathway. Oncol Lett. 2018; 15(5):6077-6086. PMC: 5920380. DOI: 10.3892/ol.2018.8142. View

10.

Zhou H, Zhang L, Chen Y, Zhu C, Chen F, Li A . Research progress on the hedgehog signalling pathway in regulating bone formation and homeostasis. Cell Prolif. 2021; 55(1):e13162. PMC: 8780935. DOI: 10.1111/cpr.13162. View

11.

Zhu H, Lo H . The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases. Curr Genomics. 2010; 11(4):238-45. PMC: 2930663. DOI: 10.2174/138920210791233108. View

12.

Kinzler K, Bigner S, Bigner D, Trent J, Law M, OBrien S . Identification of an amplified, highly expressed gene in a human glioma. Science. 1987; 236(4797):70-3. DOI: 10.1126/science.3563490. View

13.

Ma X, Chen K, Huang S, Zhang X, Adegboyega P, Evers B . Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis. 2005; 26(10):1698-705. DOI: 10.1093/carcin/bgi130. View

14.

Khatib Z, Matsushime H, Valentine M, Shapiro D, Sherr C, Look A . Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res. 1993; 53(22):5535-41. View

15.

Gupta S, Takebe N, LoRusso P . Targeting the Hedgehog pathway in cancer. Ther Adv Med Oncol. 2011; 2(4):237-50. PMC: 3126020. DOI: 10.1177/1758834010366430. View

16.

Yao Z, Han L, Chen Y, He F, Sun B, Kamar S . Hedgehog signalling in the tumourigenesis and metastasis of osteosarcoma, and its potential value in the clinical therapy of osteosarcoma. Cell Death Dis. 2018; 9(6):701. PMC: 5999604. DOI: 10.1038/s41419-018-0647-1. View

17.

Pandith A, Siddiqi M . Burden of cancers in the valley of Kashmir: 5 year epidemiological study reveals a different scenario. Tumour Biol. 2012; 33(5):1629-37. DOI: 10.1007/s13277-012-0418-z. View

18.

Rasool S, Kadla S, Rasool V, Ganai B . A comparative overview of general risk factors associated with the incidence of colorectal cancer. Tumour Biol. 2013; 34(5):2469-76. DOI: 10.1007/s13277-013-0876-y. View

19.

Rawla P, Sunkara T, Barsouk A . Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol. 2019; 14(2):89-103. PMC: 6791134. DOI: 10.5114/pg.2018.81072. View

20.

Binefa G, Rodriguez-Moranta F, Teule A, Medina-Hayas M . Colorectal cancer: from prevention to personalized medicine. World J Gastroenterol. 2014; 20(22):6786-808. PMC: 4051918. DOI: 10.3748/wjg.v20.i22.6786. View